NCT04994977View on ClinicalTrials.gov

Intra-Arterial Chemotherapy for Newly Diagnosed, Residual, or Recurrent Atypical Choroid Plexus Papilloma and Choroid Plexus Carcinoma Prior to Second-Look Surgery

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 4, 2023

Primary Completion Date

July 23, 2024

Study Completion Date

December 31, 2026

Conditions

Atypical Choroid Plexus PapillomaChoroid Plexus Carcinoma

Interventions

DRUG

Melphalan

Given at 0.5 mg/ml.

DRUG

Carboplatin

Given at 5 mg/ml.

DRUG

Topotecan

Given at 0.2 mg/ml.

Trial Locations (1)

10025

Weill Cornell Medicine, New York

All Listed Sponsors

lead

Weill Medical College of Cornell University

OTHER

NCT04994977 - Intra-Arterial Chemotherapy for Newly Diagnosed, Residual, or Recurrent Atypical Choroid Plexus Papilloma and Choroid Plexus Carcinoma Prior to Second-Look Surgery | Biotech Hunter | Biotech Hunter